Grace Therapeutics, Inc.GRCEEarnings & Financial Report
Nasdaq
Delix Therapeutics is an American biotech company based in Boston, Massachusetts. The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD). It was co-founded in 2019 by David E. Olson and Nick Haft.
GRCE Q3 2022 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-4.5M
Net Profit
$-3.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.09
Grace Therapeutics, Inc. Q3 2022 Financial Summary
Grace Therapeutics, Inc. reported revenue of $0 for Q3 2022, with a net profit of $-3.8M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-3.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2022 |
Income Statement
| Q3 2022 | |
|---|---|
| Revenue | $0 |
| YoY Growth | N/A |
Balance Sheet
| Q3 2022 | |
|---|---|
| Assets | $114.2M |
| Liabilities | $3.2M |
| Equity | $111.1M |
Cash Flow
| Q3 2022 | |
|---|---|
| Operating CF | $-4.6M |